Popular Alternatives to Meld for Mac. Explore 23 Mac apps like Meld, all suggested and ranked by the AlternativeTo user community. The first, I think, good solution I found was a replacement for the awesome tool that is MELD because at the time of writing this, the Mac OS port is not yet finished and building from source is not something I want to do as a noob.

When different developers on the same code it is work, it is useful to quickly get the result to compare with a program that is especially focused on. In English, it is a 'diff and merge' program called, i.e. software code to compare and merge.

Sign is an open source code tool suitable for all popular operating systems.

Sign is a free software tool for comparing and merging source code. It compares the code in real-time between two or three different folders. The automatic syntax background colors make it easier to programmeurcode to read. Conflicts related to the merge of the code to be in a red color indicated.

Sign supports many popular version control systems including Git, SVN, Bazaar and Mercurial. This is the status of different versions is shown, and for your code to commit the compare starts so you can see what changes have all been made.

Sign has the following characteristics:

• open source code vergelijkingssoftware,
• suitable for programmers who codes compare and merge,
• comparison between codes is real-time made,
• easily navigate between differences and conflicts,
• all and local differences to visualize,
• automatic syntax makering with background colors,
• two or three folders automatic file-by-file compare,
• merge feature supports existing version control systems,
• supports, among other Bazaar, SVN, Mercurial and Git,
• suitable for Linux, Mac and Windows systems.

Sign screenshots

Meld For Mac Os X

You can free download Meld and safe install the latest trial or new full version for Windows 10 (x32, 64 bit, 86) from the official site.

Devices: Desktop PC, Laptop (ASUS, HP, DELL, Acer, Lenovo, MSI), Ultrabook

Meld Merge Tool

OS: Professional, Enterprise, Education, Home Edition, versions: 1507, 1511, 1607, 1703, 1709, 1803, 1809

The Model for End-Stage Liver Disease, or MELD, is a scoring system for assessing the severity of chronic liver disease. It was initially developed to predict mortality within three months of surgery in patients who had undergone a transjugular intrahepatic portosystemic shunt (TIPS) procedure,^[1] and was subsequently found to be useful in determining prognosis and prioritizing for receipt of a liver transplant.^[2][3] This score is now used by the United Network for Organ Sharing (UNOS) and Eurotransplant for prioritizing allocation of liver transplants instead of the older Child-Pugh score.^[3][4]

Determination[edit]

MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. It is calculated according to the following formula:^[3]

MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43

MELD scores are reported as whole numbers, so the result of the equation above is rounded.

UNOS has made the following modifications to the score:^[5]

• If the patient has been dialyzed twice within the last 7 days, then the value for serum creatinine used should be 4.0 mg/dL
• Any value less than one is given a value of 1 (i.e. if bilirubin is 0.8 a value of 1.0 is used) to prevent subtraction from any of the three factors, since the natural logarithm of a positive number below 1 (greater than 0 and less than 1) yields a negative value.

The etiology of liver disease was subsequently removed from the model because it posed difficulties such as how to categorize patients with multiple causes of liver disease. Modification of the MELD score by excluding etiology of liver disease did not significantly affect the model's accuracy in predicting three-month survival.

Patients with a diagnosis of liver cancer will be assigned a MELD score based on how advanced the cancer is.^{[citation needed]}

Interpretation[edit]

In interpreting the MELD Score in hospitalized patients, the 3 month observed mortality (considering 3437 adult liver transplant candidates with chronic liver disease who were added tothe OPTN waiting list at 2A or 2B status between November, 1999, and December, 2001) is:^[6]

• 40 or more — 71.3% observed mortality
• 30–39 — 52.6% observed mortality
• 20–29 — 19.6% observed mortality
• 10–19 — 6.0% observed mortality
• <9 — 1.9% observed mortality

Applications of MELD score:

• The best outcomes with TIPS occur among patients with a MELD score less than 14.
• Patients with MELD scores greater than 24 who are reasonable liver transplant candidates are probably best served by foregoing TIPS placement.

Meld Macbook

History[edit]

MELD was originally developed at the Mayo Clinic by Dr. Patrick Kamath, and at that point was called the 'Mayo End-stage Liver Disease' score. It was derived in a series of patients undergoing TIPS procedures. The original version also included a variable based on the underlying etiology (cause) of the liver disease.^[1] The score turned out to be predictive of prognosis in chronic liver disease in general, and–with some modifications–came to be applied as an objective tool in assigning need for a liver transplant. The etiology turned out to be relatively unimportant, and was also regarded as relatively subjective; it was therefore removed from the score.^[3]

MELD-Plus, a new score resulted from a collaboration between Massachusetts General Hospital and IBM was introduced in 2017.^[7]

Potential of alternative scores to extend life expectancy[edit]

United Network for Organ Sharing proposed that MELD-Na score (an extension of MELD) may better rank candidates based on their risk of pre-transplant mortality and is projected to save 50-60 lives total per year.^[8] Furthermore, a study published in the New England Journal of Medicine in 2008, estimated that using MELD-Na instead of MELD would save 90 lives for the period from 2005 to 2006.^[9] In his viewpoint published in June 2018, co-creator of MELD-Plus, Uri Kartoun, suggested that ' ...MELD-Plus, if incorporated into hospital systems, could save hundreds of patients every year in the United States alone.'^[10]

See also[edit]

References[edit]

1. ^ ^abMalinchoc, Michael; Kamath, Patrick S; Gordon, Fredric D; Peine, Craig J; Rank, Jeffrey; Ter Borg, Pieter C.J (2000). 'A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts'. Hepatology. 31 (4): 864–71. doi:10.1053/he.2000.5852. PMID10733541.
2. ^Kamath, P; Wiesner, R. H; Malinchoc, M; Kremers, W; Therneau, T. M; Kosberg, C. L; d'Amico, G; Dickson, E. R; Kim, W. R (2001). 'A model to predict survival in patients with end-stage liver disease'. Hepatology. 33 (2): 464–70. doi:10.1053/jhep.2001.22172. PMID11172350.
3. ^ ^abcdKamath, Patrick S; Kim, W. Ray (2007). 'The model for end-stage liver disease (MELD)'. Hepatology. 45 (3): 797–805. doi:10.1002/hep.21563. PMID17326206.
4. ^Jung, G.E; Encke, J; Schmidt, J; Rahmel, A (2008). 'Model for end-stage liver disease'. Der Chirurg. 79 (2): 157–63. doi:10.1007/s00104-008-1463-4. PMID18214398.
5. ^UNOS (2009-01-28). 'MELD/PELD calculator documentation'(PDF). Retrieved 2010-02-21.
6. ^Wiesner, Russell; Edwards, Erick; Freeman, Richard; Harper, Ann; Kim, Ray; Kamath, Patrick; Kremers, Walter; Lake, John; Howard, Todd; Merion, Robert M; Wolfe, Robert A; Krom, Ruud; United Network for Organ Sharing Liver Disease Severity Score Committee (2003). 'Model for end-stage liver disease (MELD) and allocation of donor livers'. Gastroenterology. 124 (1): 91–6. doi:10.1053/gast.2003.50016. PMID12512033.
7. ^Kartoun, Uri; Corey, Kathleen E; Simon, Tracey G; Zheng, Hui; Aggarwal, Rahul; Ng, Kenney; Shaw, Stanley Y (2017). 'The MELD-Plus: A generalizable prediction risk score in cirrhosis'. PLOS One. 12 (10): e0186301. doi:10.1371/journal.pone.0186301. PMC5656314. PMID29069090.
8. ^https://optn.transplant.hrsa.gov/media/1834/liver_boardreport_20140702.pdf
9. ^Kim, WR; Biggins, SW; Kremers, WK; Wiesner, RH; Kamath, PS; Benson, JT; Edwards, E; Therneau, TM (2008). 'Hyponatremia and mortality among patients on the liver-transplant waiting list'. N Engl J Med. 359 (10): 1018–6. doi:10.1056/NEJMoa0801209. PMC4374557. PMID18768945.
10. ^Kartoun, Uri (2018). 'Toward an accelerated adoption ofmw-data:TemplateStyles:r886058088'>

External links[edit]

• Mobile friendly MELD score by MedWebApp
• Model for End-Stage Liver Disease Calculator by MDCalc